MML Investors Services LLC acquired a new position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,036 shares of the medical instruments supplier’s stock, valued at approximately $504,000.
Other institutional investors also recently added to or reduced their stakes in the company. Neuburgh Advisers LLC increased its stake in shares of Merit Medical Systems by 2.9% in the fourth quarter. Neuburgh Advisers LLC now owns 6,204 shares of the medical instruments supplier’s stock valued at $346,000 after buying an additional 176 shares in the last quarter. Flinton Capital Management LLC boosted its holdings in Merit Medical Systems by 2.9% in the fourth quarter. Flinton Capital Management LLC now owns 9,588 shares of the medical instruments supplier’s stock valued at $535,000 after acquiring an additional 272 shares during the last quarter. Comerica Bank boosted its holdings in Merit Medical Systems by 0.6% in the fourth quarter. Comerica Bank now owns 54,289 shares of the medical instruments supplier’s stock valued at $2,897,000 after acquiring an additional 297 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Merit Medical Systems by 8.7% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,802 shares of the medical instruments supplier’s stock valued at $212,000 after acquiring an additional 303 shares during the last quarter. Finally, First Mercantile Trust Co. boosted its holdings in Merit Medical Systems by 7.5% in the fourth quarter. First Mercantile Trust Co. now owns 4,429 shares of the medical instruments supplier’s stock valued at $247,000 after acquiring an additional 310 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.
Several research firms recently issued reports on MMSI. Zacks Investment Research cut Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Monday, December 31st. BidaskClub cut Merit Medical Systems from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $67.60.
Shares of NASDAQ:MMSI traded down $2.70 during trading on Wednesday, hitting $56.50. 1,153,900 shares of the company’s stock traded hands, compared to its average volume of 373,183. Merit Medical Systems, Inc. has a 52 week low of $44.05 and a 52 week high of $66.34. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.45 and a quick ratio of 1.32. The stock has a market capitalization of $3.17 billion, a PE ratio of 33.43, a price-to-earnings-growth ratio of 2.47 and a beta of 1.11.
Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings data on Tuesday, April 23rd. The medical instruments supplier reported $0.37 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.36 by $0.01. Merit Medical Systems had a return on equity of 11.26% and a net margin of 4.76%. The business had revenue of $238.35 million for the quarter, compared to analysts’ expectations of $236.53 million. During the same quarter in the previous year, the business posted $0.31 EPS. Merit Medical Systems’s revenue for the quarter was up 17.4% on a year-over-year basis. On average, research analysts expect that Merit Medical Systems, Inc. will post 2.01 earnings per share for the current year.
Merit Medical Systems Profile
Merit Medical Systems, Inc manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions.
Featured Story: Cost of Debt
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.